Novocure Stock EBITDA
NVCR Stock | USD 12.24 0.56 4.38% |
Novocure fundamentals help investors to digest information that contributes to Novocure's financial success or failures. It also enables traders to predict the movement of Novocure Stock. The fundamental analysis module provides a way to measure Novocure's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novocure stock.
Last Reported | Projected for Next Year | ||
EBITDA | -176.7 M | -167.8 M |
Novocure | EBITDA |
Novocure Company EBITDA Analysis
Novocure's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Novocure EBITDA | (176.66 M) |
Most of Novocure's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novocure is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Novocure EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Novocure is extremely important. It helps to project a fair market value of Novocure Stock properly, considering its historical fundamentals such as EBITDA. Since Novocure's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novocure's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novocure's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition |
Novocure Ebitda
According to the company disclosure, Novocure reported earnings before interest,tax, depreciation and amortization of (176.66 Million). This is 120.13% lower than that of the Health Care Equipment & Supplies sector and 137.55% lower than that of the Health Care industry. The ebitda for all United States stocks is 104.53% higher than that of the company.
Novocure EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novocure's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novocure could also be used in its relative valuation, which is a method of valuing Novocure by comparing valuation metrics of similar companies.Novocure is currently under evaluation in ebitda category among related companies.
Novocure Current Valuation Drivers
We derive many important indicators used in calculating different scores of Novocure from analyzing Novocure's financial statements. These drivers represent accounts that assess Novocure's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Novocure's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 8.2B | 17.5B | 7.8B | 7.7B | 1.6B | 1.5B | |
Enterprise Value | 8.2B | 17.7B | 8.1B | 8.1B | 1.9B | 1.8B |
Novocure Institutional Holders
Institutional Holdings refers to the ownership stake in Novocure that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Novocure's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Novocure's value.Shares | Nordwand Advisors Llc | 2023-12-31 | 1.5 M | Two Sigma Investments Llc | 2023-12-31 | 1.5 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.4 M | Millennium Management Llc | 2023-12-31 | 1.1 M | Norges Bank | 2023-12-31 | 974 K | Credit Suisse First Boston (csfb) | 853.5 K | Frontier Capital Management Co Inc | 2023-12-31 | 793.5 K | Qube Research & Technologies | 2023-12-31 | 773.8 K | Bank Of America Corp | 2023-12-31 | 678.6 K | Fmr Inc | 2023-12-31 | 16 M | Vanguard Group Inc | 2023-12-31 | 9.8 M |
Novocure Fundamentals
Return On Equity | -0.52 | ||||
Return On Asset | -0.12 | ||||
Profit Margin | (0.41) % | ||||
Operating Margin | (0.34) % | ||||
Current Valuation | 1.06 B | ||||
Shares Outstanding | 107.61 M | ||||
Shares Owned By Insiders | 9.25 % | ||||
Shares Owned By Institutions | 85.26 % | ||||
Number Of Shares Shorted | 6.04 M | ||||
Price To Earning | 721.15 X | ||||
Price To Book | 4.01 X | ||||
Price To Sales | 2.85 X | ||||
Revenue | 509.34 M | ||||
Gross Profit | 423.58 M | ||||
EBITDA | (176.66 M) | ||||
Net Income | (207.04 M) | ||||
Cash And Equivalents | 948.52 M | ||||
Cash Per Share | 9.06 X | ||||
Total Debt | 596.24 M | ||||
Debt To Equity | 1.31 % | ||||
Current Ratio | 8.08 X | ||||
Book Value Per Share | 3.38 X | ||||
Cash Flow From Operations | (73.34 M) | ||||
Short Ratio | 3.46 X | ||||
Earnings Per Share | (1.95) X | ||||
Price To Earnings To Growth | (0.47) X | ||||
Target Price | 27.33 | ||||
Number Of Employees | 1.45 K | ||||
Beta | 0.43 | ||||
Market Capitalization | 1.35 B | ||||
Total Asset | 1.15 B | ||||
Retained Earnings | (985.5 M) | ||||
Working Capital | 855.29 M | ||||
Current Asset | 293.9 M | ||||
Current Liabilities | 28.63 M | ||||
Net Asset | 1.15 B |
About Novocure Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novocure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novocure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novocure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Novocure Investors Sentiment
The influence of Novocure's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novocure. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novocure's public news can be used to forecast risks associated with an investment in Novocure. The trend in average sentiment can be used to explain how an investor holding Novocure can time the market purely based on public headlines and social activities around Novocure. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novocure's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novocure's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novocure's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novocure.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novocure in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novocure's short interest history, or implied volatility extrapolated from Novocure options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Novocure Piotroski F Score and Novocure Altman Z Score analysis. To learn how to invest in Novocure Stock, please use our How to Invest in Novocure guide.Note that the Novocure information on this page should be used as a complementary analysis to other Novocure's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Novocure Stock analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Novocure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novocure. If investors know Novocure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novocure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share (1.95) | Revenue Per Share 4.787 | Quarterly Revenue Growth 0.042 | Return On Assets (0.12) |
The market value of Novocure is measured differently than its book value, which is the value of Novocure that is recorded on the company's balance sheet. Investors also form their own opinion of Novocure's value that differs from its market value or its book value, called intrinsic value, which is Novocure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novocure's market value can be influenced by many factors that don't directly affect Novocure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novocure's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novocure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novocure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.